EDIT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Editas Medicine Inc (EDIT) is not a strong buy for a beginner, long-term investor at this time. The technical indicators are neutral to bearish, financial performance is weak, and there are no immediate positive catalysts to drive significant growth. While hedge funds are increasing their positions, the stock lacks strong momentum or clear signals for entry. It is better to wait for improved financials or stronger technical signals before considering investment.
The MACD is negatively expanding, RSI is neutral at 47.296, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot level of 2.416, with resistance at 2.572 and support at 2.259.
Hedge funds are significantly increasing their positions, with a 500.44% increase in buying over the last quarter. Analyst Soumit Roy upgraded the stock to 'Buy' with an $8 price target, citing the upcoming IND/CTA submission for EDIT-401.
No recent news or congress trading data is available to indicate immediate positive momentum.
In Q4 2025, revenue dropped by -19.16% YoY to $24.74M, net income decreased by -87.62% YoY to -$5.62M, and EPS fell by -89.09% YoY to -0.06. Gross margin remained stable at 100%.
Analyst Soumit Roy from JonesResearch upgraded the stock to 'Buy' with an $8 price target, citing the potential of EDIT-401, which is expected to launch in 2031.
